Article
Cell Biology
Kai Nie, Jun Yi, Yuanyuan Yang, Minzi Deng, Yan Yang, Tianyu Wang, Xuejie Chen, Zhaoyu Zhang, Xiaoyan Wang
Summary: The study found that m6A regulation plays a significant role in the occurrence and development of inflammatory bowel disease (IBD), influencing different subtypes and therapeutic responses in IBD. m6A modification involves methyltransferases, demethylases, and methylation-reading proteins, affecting the pathophysiology and clinical phenotypes of the disease through regulation of IBD risk genes and core cytokines.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Raaj S. Mehta, Jared R. Mayers, Yancong Zhang, Amrisha Bhosle, Nathaniel R. Glasser, Long H. Nguyen, Wenjie Ma, Sena Bae, Tobyn Branck, Kijun Song, Luke Sebastian, Julian Avila Pacheco, Hyuk-Soo Seo, Clary Clish, Sirano Dhe-Paganon, Ashwin N. Ananthakrishnan, Eric A. Franzosa, Emily P. Balskus, Andrew T. Chan, Curtis Huttenhower
Summary: A multi-omics workflow was used to identify the microbial pathways responsible for the degradation of the drug 5-ASA in patients with inflammatory bowel disease. The study found 12 previously uncharacterized microbial acetyltransferases associated with 5-ASA inactivation. In addition, three microbial thiolases and one acyl-CoA N-acyltransferase were found to be epidemiologically associated with an increased risk of treatment failure among 5-ASA users.
Article
Pharmacology & Pharmacy
Martina Tallarico, Caterina Palleria, Livia Ruffolo, Rocco Spagnuolo, Maria Diana Naturale, Adele Emanuela De Francesco, Caterina De Sarro, Rossella Romeo, Rita Citraro, Patrizia Doldo, Ludovico Abenavoli, Luca Gallelli, Francesco Luzza, Antonio Leo, Giovambattista De Sarro
Summary: This study aimed to evaluate the occurrence of adverse events and therapeutic failures in patients treated with biological agents for inflammatory bowel diseases and found that the rate of adverse events was low in the observed patients.
Review
Gastroenterology & Hepatology
Apostolis Papaefthymiou, Spyros Potamianos, Antonis Goulas, Michael Doulberis, Jannis Kountouras, Stergios A. Polyzos
Summary: Inflammatory bowel diseases (IBD) and nonalcoholic fatty liver disease (NAFLD) may be associated, but the relationship between the two is complex and requires further research. Biologic agents may have a potential therapeutic benefit for IBD-associated NAFLD, but their specific effects need to be clarified.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Chemistry, Applied
Barbara Hufnagel, Verena Muellner, Katharina Hlatky, Claudia Tallian, Robert Vielnascher, Georg M. Guebitz, Michael Wirth, Franz Gabor
Summary: This study explored a new preparation technique for pellets made from acetylated inulin to achieve specific intestinal delivery of 5-aminosalicylic acid. The acetylated inulins were insoluble in water with increased hydrophobicity, and showed high drug loading capacity and release rate, offering a promising new strategy for the treatment of Crohn's disease and ulcerative colitis.
CARBOHYDRATE POLYMERS
(2021)
Review
Gastroenterology & Hepatology
Chrong-Reen Wang, Hung-Wen Tsai
Summary: Seronegative spondyloarthropathy (SpA) is a disease that commonly affects individuals in their third decade of life and is characterized by negative rheumatoid factor, human leukocyte antigen-B27 genetic marker, and various clinical features. The management of SpA-associated inflammatory bowel disease (IBD) remains to be established, with different treatment options available for peripheral and axial SpA, as well as IBD.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Polymer Science
Cristina Elena Stavarache, Adi Ghebaur, Sorina Dinescu, Iuliana Samoila, Eugeniu Vasile, George Mihail Vlasceanu, Horia Iovu, Sorina Alexandra Garea
Summary: The aim of this study was to prepare mucoadhesive particles using biopolymers and 5-aminosalicylic acid for controlled drug release at the colon level, with potential applications in the treatment of intestinal bowel disease. The particles were prepared through crosslinking of chitosan with sodium tripolyphosphate and the influence of k-carrageenan layer was studied. Encapsulation efficiency and drug release profile of 5ASA were assessed using UV-VIS spectrometry, while chemical characterization was done using FT-IR spectrometry. The results suggest that these particle systems could be a versatile platform for targeted drug delivery in inflammatory bowel disease treatment.
Review
Gastroenterology & Hepatology
Eric Cheah, James Guoxian Huang
Summary: The introduction of biologics and small molecules has greatly improved the prognosis and quality of life in inflammatory bowel disease (IBD). Biosimilars have increased affordability and access to targeted therapies. However, some patients do not respond to first-line anti-TNF agents, and it is unclear which patients would benefit from different sequencing or combinations of biologic agents. New classes of biologics and small molecules may provide alternative therapeutic options for refractory disease. This review explores the current treatment strategies for IBD and potential future shifts in paradigms.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Review
Medicine, General & Internal
Shintaro Akiyama, Joshua M. Steinberg, Mariko Kobayashi, Hideo Suzuki, Kiichiro Tsuchiya
Summary: Inflammatory bowel disease (IBD) is more common in young women during their peak reproductive years. Women with active IBD during pregnancy have a higher risk of disease relapse, leading to poor outcomes for both mother and baby. Achieving disease remission before conception is ideal, but some patients may experience flare-ups during pregnancy. Medication for IBD should be continued to reduce the risk of flare-ups and poor outcomes. Treatment for IBD flare-ups during pregnancy is similar to non-pregnant patients, including the use of 5-aminosalicylates, steroids, calcineurin inhibitors, and biologic therapies. The safety of calcineurin inhibitors in pregnant women with IBD is limited, but recent findings suggest they may be safer than in solid organ transplant recipients. Physicians should have a thorough understanding of the benefits and safety profiles of biologics and small molecules for pregnant women with IBD.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Article
Gastroenterology & Hepatology
Anthony Buisson, Melanie Serrero, Laurie Orsat, Stephane Nancey, Pauline Riviere, Romain Altwegg, Laurent Peyrin-Biroulet, Maria Nachury, Xavier Hebuterne, Cyrielle Gilletta, Mathurin Flamant, Stephanie Viennot, Guillaume Bouguen, Aurelien Amiot, Stephane Mathieu, Lucine Vuitton, Laurianne Plastaras, Arnaud Bourreille, Ludovic Caillo, Felix Goutorbe, Guillaume Pineton De Chambrun, Alain Attar, Xavier Roblin, Bruno Pereira, Mathurin Fumery
Summary: This study compared the acceptability of different maintenance regimens in patients with inflammatory bowel disease (IBD). The results showed that the acceptability of treatment was highly influenced by the route of administration and prior medication exposures. Subcutaneous injections with intervals of 8 weeks or longer and oral intake once daily were the most accepted modalities.
INFLAMMATORY BOWEL DISEASES
(2023)
Review
Gastroenterology & Hepatology
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu Inoue, Toshiyuki Itoh, Makoto Naganuma, Tadakazu Hisamatsu, Mamoru Watanabe, Hiroto Miwa, Nobuyuki Enomoto, Tooru Shimosegawa, Kazuhiko Koike
Summary: Inflammatory bowel disease (IBD) encompasses chronic or remitting/relapsing inflammatory diseases of the intestinal tract, including ulcerative colitis (UC) and Crohn's disease (CD). The etiology of IBD involves disease susceptibility genes, environmental factors, and intestinal bacteria. Optimal management depends on evidence-based interventions tailored by physicians.
JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Medicine, General & Internal
Claudia Herrera-deGuise, Xavier Serra-Ruiz, Ernesto Lastiri, Natalia Borruel
Summary: Inflammatory bowel disease (IBD) is a chronic immune-mediated condition of the gastrointestinal tract. New monoclonal antibodies targeting specific cytokines have been dominant in IBD treatment, but many patients experience incomplete response or adverse events. Janus kinase (JAK) is important in modulating signal transduction pathways involved in gastrointestinal inflammation and may be a promising target for IBD treatment.
FRONTIERS IN MEDICINE
(2023)
Review
Gastroenterology & Hepatology
Yi-Han Xu, Wei-Ming Zhu, Zhen Guo
Summary: Treatment strategies for inflammatory bowel disease are evolving with the development of biologics and small molecule drugs. However, not all patients respond to these drugs, leading to a need for optimizing their use and predicting therapeutic responses. The development of new drugs with novel mechanisms is urgently needed, as is the exploration of combination therapies to enhance treatment efficacy.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
George Khoudari, Emad Mansoor, Benjamin Click, Motasem Alkhayyat, Mohannad Abou Saleh, Preetika Sinh, Jeffry Katz, Gregory S. Cooper, Miguel Regueiro
Summary: In this study, it was found that inflammatory bowel disease (IBD) patients treated with biologics were significantly less likely to undergo bowel resection when compared to those who never received biologics. This suggests that biologics may impact surgical rates in IBD patients.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Review
Rheumatology
Maedeh Ashrafi, Kristine A. Kuhn, Michael H. Weisman
Summary: IBD-associated arthritis, a subgroup of spondyloarthritis, has historically lacked recognition in rheumatology, but advances in detection systems have led to a better understanding of the complex connection between the gut and musculoskeletal system. Current research points to dysregulated microbiome, immune cell migration, and adhesion molecules as key factors in driving IBD-arthritis, highlighting the need for further exploration in this field.
